| __timestamp | Blueprint Medicines Corporation | Opthea Limited |
|---|---|---|
| Wednesday, January 1, 2014 | 7890000 | 2652041 |
| Thursday, January 1, 2015 | 14456000 | 2361587 |
| Friday, January 1, 2016 | 19218000 | 4472869 |
| Sunday, January 1, 2017 | 27986000 | 5030957 |
| Monday, January 1, 2018 | 47928000 | 4988941 |
| Tuesday, January 1, 2019 | 96388000 | 5196412 |
| Wednesday, January 1, 2020 | 157743000 | 6652774 |
| Friday, January 1, 2021 | 195293000 | 18418247 |
| Saturday, January 1, 2022 | 237374000 | 24827066 |
| Sunday, January 1, 2023 | 295141000 | 41896408 |
| Monday, January 1, 2024 | 359272000 | 15488619 |
Cracking the code
In the competitive landscape of biotechnology, operational efficiency is key. Blueprint Medicines Corporation and Opthea Limited, two prominent players, have shown contrasting trends in their Selling, General, and Administrative (SG&A) expenses from 2014 to 2023. Blueprint Medicines has seen a staggering increase of over 3,600% in SG&A expenses, peaking at approximately $295 million in 2023. This reflects their aggressive expansion and investment in operational capabilities. In contrast, Opthea Limited's SG&A expenses grew by around 1,500%, reaching about $42 million in the same year. This more conservative growth suggests a different strategic focus, possibly prioritizing cost control. Notably, 2024 data for Blueprint Medicines is missing, indicating potential reporting delays or strategic shifts. These insights highlight the diverse strategies within the biotech sector, where financial management can significantly impact a company's trajectory.
Selling, General, and Administrative Costs: Eli Lilly and Company vs Opthea Limited
Who Optimizes SG&A Costs Better? AbbVie Inc. or Blueprint Medicines Corporation
Comparing SG&A Expenses: Sanofi vs Opthea Limited Trends and Insights
Bristol-Myers Squibb Company and Blueprint Medicines Corporation: SG&A Spending Patterns Compared
Operational Costs Compared: SG&A Analysis of Vertex Pharmaceuticals Incorporated and Opthea Limited
Comparing SG&A Expenses: Regeneron Pharmaceuticals, Inc. vs Blueprint Medicines Corporation Trends and Insights
Genmab A/S and Opthea Limited: SG&A Spending Patterns Compared
Blueprint Medicines Corporation and Bausch Health Companies Inc.: SG&A Spending Patterns Compared
Blueprint Medicines Corporation vs Taro Pharmaceutical Industries Ltd.: SG&A Expense Trends
Cost Management Insights: SG&A Expenses for Pharming Group N.V. and Opthea Limited
Opthea Limited vs Alpine Immune Sciences, Inc.: SG&A Expense Trends
Cost Management Insights: SG&A Expenses for Opthea Limited and Mesoblast Limited